ESTRO 2024 - Abstract Book

S2585

Clinical - Urology

ESTRO 2024

Conclusion:

Multifocal MIB utilizing robotic SBRT is feasible and with early follow-up yielded no significant difference in GU or GI toxicity. There is also no difference in patient reported EPIC bowel summary scores. However, there may be subtle transient differences in EPIC urinary quality of life observed in both the unifocal and multifocal MIB group. Future research should explore longer-term toxicity and quality of life outcomes with a larger cohort.

Keywords: Prostate, SBRT, Microboost,

2911

Poster Discussion

Localised prostate cancer, time to rethink RT volumes-MRI & pathological correlation in 375 patients

Babusha Kalra 1 , Akanksha Singh 1 , Steve Hazell 2 , Declan Cahill 3 , Erik Mayer 3 , Sam Withey 4 , Aslam Sohaib 4 , Angela Pathmanathan 1,5 , Alison Tree 1,5 1 The Royal Marsden Hospital, UroOncology, Sutton, United Kingdom. 2 The Royal Marsden Hospital, Pathology, Sutton, United Kingdom. 3 The Royal Marsden Hospital, Urology, Chelsea, United Kingdom. 4 The Royal Marsden Hospital, Radiology, Sutton, United Kingdom. 5 Institute of Cancer research, UroOncology, Sutton, United Kingdom

Purpose/Objective:

Prostate cancer is the second most commonly diagnosed cancer and fifth leading cause of cancer death among men worldwide. Organ confined prostate cancer constitutes nearly 77% of total prostate cancer burden. Clinical practice and many clinical guidelines suggest including entire prostate and 1 cm of proximal seminal vesicles in the clinical target volume in patients with disease limited to the prostate. In the era of multi parametric MRI (mp MRI) diagnostic imaging can help stage patients accurately prior to local treatment. We aim to assess concordance of